Growth/Differentiation Factor 8 - Pipeline Review, H2 2020
Growth/Differentiation Factor 8 - Pipeline Review, H2 2020
SUMMARY
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 9 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 2 respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Genetic Disorders, Hematological Disorders and Oncology which include indications Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Anemia, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuromuscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Sarcopenia and Thalassemia.
The latest report GrowthDifferentiation Factor 8 - Pipeline Review, H2 2020, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 9 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 2 respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Genetic Disorders, Hematological Disorders and Oncology which include indications Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Anemia, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuromuscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Sarcopenia and Thalassemia.
The latest report GrowthDifferentiation Factor 8 - Pipeline Review, H2 2020, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Biogen Inc
Bioleaders Corp
Chugai Pharmaceutical Co Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
ALG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apitegromab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Sep 30, 2020: Scholar Rock presents data for SRK-015 at the World Muscle Society 2020 Virtual Congress
Sep 29, 2020: Health Canada approves REBLOZYL (luspatercept), new class of treatment for adult patients living with beta thalassemia
Aug 27, 2020: Scholar Rock announces issuance of U.S. patent providing composition of matter protection for SRK-015
Aug 13, 2020: Scholar Rock announces that SRK-015 has received rare pediatric disease designation from U.S. FDA for the treatment of spinal muscular atrophy
Jun 26, 2020: European Commission approves Reblozyl (luspatercept) for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes or beta thalassemia
Jun 12, 2020: Scholar Rock presents clinical and preclinical data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting
May 20, 2020: Acceleron announces presentations on REBLOZYL (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings
May 18, 2020: Scholar Rock presents baseline demographics data from the SRK-015 TOPAZ trial at the American Academy of Neurology Conference
Apr 30, 2020: Novel drug shows promise for inherited blood disorder
Apr 30, 2020: Reblozyl (luspatercept) receives positive CHMP opinion for the treatment of adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
Apr 03, 2020: U.S. Food and Drug Administration (FDA) approves Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent, to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS)
Mar 26, 2020: New England Journal of Medicine Publishes results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
Mar 24, 2020: Scholar Rock presents data for SRK-015 at the Muscular Dystrophy Association Clinical and Scientific Conference
Feb 06, 2020: Scholar Rock presents data for SRK-015 at the SMA Europe 2nd International Scientific Congress
Jan 09, 2020: New England journal of medicine publishes results of pivotal phase 3 Reblozyl (luspatercept-aamt) MEDALIST trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Biogen Inc
Bioleaders Corp
Chugai Pharmaceutical Co Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
ALG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apitegromab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Sep 30, 2020: Scholar Rock presents data for SRK-015 at the World Muscle Society 2020 Virtual Congress
Sep 29, 2020: Health Canada approves REBLOZYL (luspatercept), new class of treatment for adult patients living with beta thalassemia
Aug 27, 2020: Scholar Rock announces issuance of U.S. patent providing composition of matter protection for SRK-015
Aug 13, 2020: Scholar Rock announces that SRK-015 has received rare pediatric disease designation from U.S. FDA for the treatment of spinal muscular atrophy
Jun 26, 2020: European Commission approves Reblozyl (luspatercept) for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes or beta thalassemia
Jun 12, 2020: Scholar Rock presents clinical and preclinical data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting
May 20, 2020: Acceleron announces presentations on REBLOZYL (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings
May 18, 2020: Scholar Rock presents baseline demographics data from the SRK-015 TOPAZ trial at the American Academy of Neurology Conference
Apr 30, 2020: Novel drug shows promise for inherited blood disorder
Apr 30, 2020: Reblozyl (luspatercept) receives positive CHMP opinion for the treatment of adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
Apr 03, 2020: U.S. Food and Drug Administration (FDA) approves Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent, to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS)
Mar 26, 2020: New England Journal of Medicine Publishes results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
Mar 24, 2020: Scholar Rock presents data for SRK-015 at the Muscular Dystrophy Association Clinical and Scientific Conference
Feb 06, 2020: Scholar Rock presents data for SRK-015 at the SMA Europe 2nd International Scientific Congress
Jan 09, 2020: New England journal of medicine publishes results of pivotal phase 3 Reblozyl (luspatercept-aamt) MEDALIST trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Acceleron Pharma Inc, H2 2020
Pipeline by Biogen Inc, H2 2020
Pipeline by Bioleaders Corp, H2 2020
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
Pipeline by PeptiDream Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Regeneron Pharmaceuticals Inc, H2 2020
Pipeline by Scholar Rock Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Acceleron Pharma Inc, H2 2020
Pipeline by Biogen Inc, H2 2020
Pipeline by Bioleaders Corp, H2 2020
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
Pipeline by PeptiDream Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Regeneron Pharmaceuticals Inc, H2 2020
Pipeline by Scholar Rock Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
